SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000926617-23-000070
Filing Date
2023-08-14
Accepted
2023-08-14 16:40:20
Documents
58
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q awh-20230630x10q.htm   iXBRL 10-Q 2675917
2 EX-31.1 awh-20230630xex31_1.htm EX-31.1 15213
3 EX-31.2 awh-20230630xex31_2.htm EX-31.2 16584
4 EX-32.1 awh-20230630xex32_1.htm EX-32.1 12149
  Complete submission text file 0000926617-23-000070.txt   8567139

Data Files

Seq Description Document Type Size
5 EX-101.SCH awh-20230630.xsd EX-101.SCH 42980
6 EX-101.CAL awh-20230630_cal.xml EX-101.CAL 51853
7 EX-101.DEF awh-20230630_def.xml EX-101.DEF 165054
8 EX-101.LAB awh-20230630_lab.xml EX-101.LAB 339924
9 EX-101.PRE awh-20230630_pre.xml EX-101.PRE 306482
52 EXTRACTED XBRL INSTANCE DOCUMENT awh-20230630x10q_htm.xml XML 1644726
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

IRS No.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34810 | Film No.: 231171302
SIC: 2835 In Vitro & In Vivo Diagnostic Substances